Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma.
K HourbeigtM EhretL VisseauxA DurlachA PetitJ SanchezA Grange-PrunierCoralie BarbeStéphanie Servagi VernatF GrangePublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
These results suggest that panitumumab remains pertinent in the treatment of unresectable cutaneous squamous cell carcinoma, in particular in association with radiotherapy, despite recent advances with anti-PD-1 antibodies. It presents several advantages: it can be used in very elderly or feeble patients, it does not provoke anaphylactic or other irreversible or life-threatening side-effects, and our study observed some long-term responses. Further prospective investigation of anti-EGFR antibodies, in association with anti-PD-1 antibodies and/or chemotherapy, should be conducted.
Keyphrases
- locally advanced
- squamous cell carcinoma
- rectal cancer
- radiation therapy
- early stage
- end stage renal disease
- small cell lung cancer
- chronic kidney disease
- ejection fraction
- newly diagnosed
- radiation induced
- epidermal growth factor receptor
- metastatic colorectal cancer
- tyrosine kinase
- prognostic factors
- lymph node metastasis
- smoking cessation